Aetna got out of the ACA marketplace business in 2018. Now CVS Health, which completed its acquisition of the insurance company in late 2018, is hopping back in and will brand the policies as a “CVS Health-Aetna” product for the first time.
Aetna got out of the ACA marketplace business in 2018. Now CVS Health, which completed its acquisition of the insurance company in late 2018, is hopping back in and will brand the policies as a “CVS Health-Aetna” product for the first time, Karen S. Lynch, the company’s new president and CEO, said during an earnings call last month.
“As the ACA has evolved, there is evidence of market stabilization and remedies to earlier structural issues,” Lynch said during the Feb. 16 call. “It is now time for us to participate in these markets.”
Lynch said CVS Health would start selling coverage that would start in January 2022, but she shared no details about how many markets the company might sell CVS Health-Aetna coverage in or which ones.
She noted that the ACA marketplace market was a big one of 10 to 15 million people. After a Supreme Court ruling favoring insurers, CVS Health was among those that received a hefty ACA risk corridor payment. The company booked a $307 million risk corridor payment in 2020.
The ACA marketplace plans may also benefit from President Joe Biden’s proposal to increase the subsidies that lower premium costs for Americans who buy ACA marketplace coverage.
CVS Health is a huge ($286.7 billion revenues last year), publicly traded company, but like many of its competitors, it has seen the proportion of its government business (Medicare Advantage, Medicaid) grow relative to its commercial business.
For example, the number of people in its insured commercial plans decreased from 3,591,000 in 2019 to 3,258,000 in 2020, a difference of 333,000, or 9.3%, according to year-end results posted at the time of the earnings call. Meanwhile, the number of people in its Medicare Advantage plans increased from 2,321,000 in 2019 to 2,705,000 in 2020, an increase of 384,000, or 16.5%.
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen